Shares of Wave Life Sciences Ltd. (WVE) gained nearly 4% on Wednesday morning after announcing positive data from the Phase 2 Forward-53 trial of WVE-N531, which is an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.
WVE is currently trading at $9.80, up $0.36 or 3.81%, on the Nasdaq. The stock opened its trading at $10.82 after closing Tuesday at $9.44. The stock has traded between $4.25 and $16.74 in the past 52-week period.
FORWARD-53 achieved all trial goals, demonstrating sustained and industry-leading exon skipping, muscle concentrations and dystrophin restoration through 48 weeks and a 61-day tissue half-life that supports monthly dosing. WVE-N531 continues to be safe and well-tolerated.
For comments and feedback: editorial@rttnews.com